Skip to content

The efficacy of complementory use of memantine in treatment of schizophrenia with chronic course

The efficacy of complementory use of memantine in treatment of schizophrenia with chronic course

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201306015605N1
Enrollment
60
Registered
2013-10-19
Start date
2012-11-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: The control group will be received Risperidone 6 mg per day and placebo (n = 30). Intervention 2: The case group will be treated with oral Risperidone 6 mg per day and 5-20 mg Memantin
Treatment - Drugs
The control group will be received Risperidone 6 mg per day and placebo (n = 30).
The case group will be treated with oral Risperidone 6 mg per day and 5-20 mg Memantine (n=30)

Sponsors

Clinical psychiatry research center, Tabriz university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Exclusion criteria: Substance abuse; IQ of less than 70; Medical history of other mental disorder; Other clinical and neurological disorders; Taking antipsychotic medications during last week or long acting antipsychotic medications during past month; Receiving ECT in the past two weeks; Sensitivity to Memantine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Schizophrenia severity. Timepoint: 6 monthes. Method of measurement: Clinical assesment.

Secondary

MeasureTime frame
Side effects. Timepoint: Two month after begining of the study. Method of measurement: Clinical assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ashkan Yousefi

Tabriz university of medical sciences

Drmgjgoldust@gmail.com+98 41 1545 2206

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026